Loading
The Orlucent System is a handheld skin imager from Orlucent that uses a fluorescent agent to judge whether a mole may be becoming melanoma. It is in clinical trials and for research use only in the United States.
The Orlucent System from Orlucent is a handheld fluorescent molecular imaging system that assesses the likelihood of a mole's transition to melanoma; the company states it is in clinical trials and for research use only in the United States. Its imaging agent ORL1 is the subject of NCI SBIR grant 1R44CA306680-01A1, which funds manufacturing controls to current Good Manufacturing Practice and reports, from preliminary studies, 100 per cent sensitivity and 95.7 per cent specificity in distinguishing melanomas from non-melanomas.
A fluorescent imaging agent, ORL1, is applied to a skin lesion and a handheld imager reads its signal to assess molecular changes linked to melanoma, as described by the company and its NCI award.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Orlucent System" OR ABSTRACT:"Orlucent System" OR TITLE:"ORL1" OR ABSTRACT:"ORL1" OR TITLE:"Orlucent Skin Fluorescent Imaging System" OR ABSTRACT:"Orlucent Skin Fluorescent Imaging System") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Orlucent System, not a curated reading list.
Shares Optical & fluorescence imaging and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/